<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="87075">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01971593</url>
  </required_header>
  <id_info>
    <org_study_id>WI170964</org_study_id>
    <nct_id>NCT01971593</nct_id>
  </id_info>
  <brief_title>The Effects of Eplerenone on Markers of Myocardial Fibrosis in Adult Congenital Heart Disease</brief_title>
  <official_title>Eplerenone to Prevent Myocardial Fibrosis in Congenital Heart Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypothesis:

      By blocking aldosterone signaling in patients with Tetralogy of Fallot, Transposition of the
      great vessels with a prior atrial switch, and single ventricle &quot;Fontan&quot; patients, incident
      heart failure will be delayed, symptoms of heart failure ameliorated, and risk of
      arrhythmias decreased through decreases in myocardial fibrosis.

      Half of enrolled patients will complete an SF-36 quality of life questionnaire, perform a 6
      minute walk, and have blood drawn for biomarker analysis at enrollment, again after 3 months
      without therapy, after 6 months on therapy, then finally after 12 months of eplerenone
      therapy. Half of enrolled patients will have the 3 month drug free period at the end of 12
      months on therapy. Patients will be randomly assigned to drug free period up front versus at
      the conclusion of the trial period. Eplerenone will be started at a dose of 25mg and
      titrated up to 50mg at 4 weeks if tolerated. Blood will be drawn for basic metabolic panel
      analysis at enrollment, 3 months, 4 months to allow for dose titration, and at 6 and 12
      months for monitoring.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Investigator left institution
  </why_stopped>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">March 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in serum markers of fibrosis.</measure>
    <time_frame>6 months and 12 months</time_frame>
    <description>Procollagen N-terminal peptide 1, Procollagen N-terminal peptide 3, Galectin 3</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>6 minute walk</measure>
    <time_frame>6 months, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>6 months, 12 months</time_frame>
    <description>SF-36</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Serum creatinine</measure>
    <time_frame>1 month, 6 months, 12 months</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Tetralogy of Fallot</condition>
  <condition>Transposition of the Great Vessels With an Arterial Switch</condition>
  <condition>Single Ventricle With a Fontan Palliation</condition>
  <arm_group>
    <arm_group_label>Eplerenone after drug free period</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients will be given eplerenone 50mg for 12 months after an initial 3 month drug free period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Eplerenone before drug free period</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients will be given eplerenone 50mg for 12 months, followed by a 3 month drug free period</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eplerenone</intervention_name>
    <arm_group_label>Eplerenone after drug free period</arm_group_label>
    <arm_group_label>Eplerenone before drug free period</arm_group_label>
    <other_name>Inspra</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Established diagnosis of tetralogy of Fallot, transposition of the great vessels with
             a systemic right ventricle, or Fontan type palliation

          -  Patient followed regularly at Washington University-affiliated institution

          -  If female, willing to use 2 forms of contraception including one barrier method
             during protocol

        Exclusion Criteria:

          -  GFR &lt;30 ml/min

          -  Potassium &gt;5.0 mmol/L

          -  Unable or unwilling to comply with study protocol

          -  Use of potassium sparing diuretics

          -  Use of an aldosterone blocker currently or previously

          -  Known intolerance of eplerenone or aldosterone blockade

          -  Pregnant, breastfeeding, or actively trying to get pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <lastchanged_date>February 16, 2016</lastchanged_date>
  <firstreceived_date>October 23, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Washington University School of Medicine</investigator_affiliation>
    <investigator_full_name>Ari Cedars</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Heart Defects, Congenital</mesh_term>
    <mesh_term>Tetralogy of Fallot</mesh_term>
    <mesh_term>Transposition of Great Vessels</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Eplerenone</mesh_term>
    <mesh_term>Spironolactone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
